The benefit of intraperitoneal chemotherapy for the treatment of colorectal carcinomatosis

Oncology Reports

Volumn 30, Issue 1, 2013, Pages 35-42

  Francescutti, Valerie ^a   Rivera, Louis ^a   Seshadri, Mukund ^a   Kim, Minhyung ^a   Haslinger, Michelle ^a   Camoriano, Marta ^a   Attwood, Kristopher ^a   Kane III, John M ^a   Skitzki, Joseph J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Carcinomatosis; Chemotherapy; Hyperthermic intraperitoneal chemoperfusion; Intraperitoneal; Mouse

Indexed keywords

MITOMYCIN; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CARCINOMATOSIS; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HYPOTHERMIA; LOW DRUG DOSE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR VOLUME;

ANIMALS; CARCINOMA; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; MICE; MICE, INBRED BALB C; MITOMYCIN; TUMOR BURDEN;

EID: 84878170178     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2473     Document Type: Article

References (20)

1. Koppe MJ, Boerman OC, Oyen WJ and Bleichrodt RP: Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 243: 212-222, 2006. (Pubitemid 43185440)
2. Siegel R, DeSantis C, Virgo K, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62: 220-241, 2012.
3. Chu DZ, Lang NP, Thompson C, Osteen PK and Westbrook KC: Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 63: 364-367, 1989. (Pubitemid 19035034)
4. Elias D, Delperro JR, Sideris L, et al: Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol 11: 518-521, 2004. (Pubitemid 40486734)
5. Sugarbaker PH: A curative approach to peritoneal carcinomatosis from colorectal cancer. Semin Oncol 32: S68-S73, 2005.
6. Glehen O, Kwiatkowski F, Sugarbaker PH, et al: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22: 3284-3292, 2004. (Pubitemid 41103684)
7. Verwaal VJ: Long-term results of cytoreduction and HIPEC followed by systemic chemotherapy. Cancer J 15: 212-215, 2009.
8. Sugarbaker PH: Peritonectomy procedures. Surg Oncol Clin N Am 12: 703-727, xiii, 2003.
9. Rossi CR, Mocellin S, Pilati P, et al: Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. Surg Oncol Clin N Am 12: 781-794, 2003.
10. van Ruth S, Verwaal VJ and Zoetmulder FA: Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am 12: 771-780, 2003.
11. Klaver YL, Hendriks T, Lomme RM, Rutten HJ, Bleichrodt RP and de Hingh IH: Hyperthermia and intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis: an experimental study. Ann Surg 254: 125-130, 2011.
12. Cohen MS, Al-Kasspooles MF, Williamson SK, Henry D, Broward M and Roby KF: Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo. Ann Surg Oncol 17: 296-303, 2010.
13. Pelz JO, Doerfer J, Hohenberger W and Meyer T: A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis. BMC Cancer 5: 56, 2005.
14. Bevanda M, Orsolic N, Basic I, et al: Prevention of peritoneal carcinomatosis in mice with combination hyperthermal intraperitoneal chemotherapy and IL-2. Int J Hyperthermia 25: 132-140, 2009.
15. Zahedi P, De Souza R, Piquette-Miller M and Allen C: Docetaxel distribution following intraperitoneal administration in mice. J Pharm Pharm Sci 14: 90-99, 2011.
16. Aarts F, Hendriks T, Boerman OC, Oyen WJ and Bleichrodt RP: Hyperthermia and fibrinolytic therapy do not improve the beneficial effect of radioimmunotherapy following cytoreductive surgery in rats with peritoneal carcinomatosis of colorectal origin. Cancer Biother Radiopharm 23: 301-309, 2008. (Pubitemid 351931462)
17. Hartmann J, Kilian M, Atanassov V, Braumann C, Ordemann J and Jacobi CA: First surgical tumour reduction of peritoneal surface malignancy in a rat's model. Clin Exp Metastasis 25: 445-449, 2008.
18. Bouquet W, Deleye S, Staelens S, et al: Antitumour efficacy of two paclitaxel formulations for hyperthermic intraperitoneal chemotherapy (HIPEC) in an in vivo rat model. Pharm Res 28: 1653-1660, 2011.
19. Gesson-Paute A, Ferron G, Thomas F, de Lara EC, Chatelut E and Querleu D: Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study. Ann Surg Oncol 15: 339-344, 2008.
20. Muller H, Hahn M, Weller L and Simsa J: Strategies to reduce perioperative morbidity in cytoreductive surgery. Hepatogastroenterology 55: 1523-1529, 2008.